Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between Washington and a drug company, will allow funding to move around GSK's antibiotics portfolio rather than focusing on a single drug candidate. The rise of antibiotic resistance is causing alarm among governments worldwide, leading to warnings from officials such as England's chief medical officer Sally Davies that the issue is a "ticking time bomb" threatening public health.
Help employers find you! Check out all the jobs and post your resume.
The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between Washington and a drug company, will allow funding to move around GSK's antibiotics portfolio rather than focusing on a single drug candidate. The rise of antibiotic resistance is causing alarm among governments worldwide, leading to warnings from officials such as England's chief medical officer Sally Davies that the issue is a "ticking time bomb" threatening public health.
Help employers find you! Check out all the jobs and post your resume.
